# 2026-15887: FDA Wants Ideas for Sci-Fi Drug Network Revolutionizing Medicine

2026-15887, Establishment of a Quantitative Medicine Innovation Network: Scope, Feasibility, and Opportunities; Request for Information, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-08-05, effective 2026-11-03 (as of 2026-08-12).

- Canonical: https://policyrisk.com/federal-register/2026-15887
- As of: 2026-08-12
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-15887
- Title: Establishment of a Quantitative Medicine Innovation Network: Scope, Feasibility, and Opportunities; Request for Information
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 50553
- Published: 2026-08-05
- Effective: 2026-11-03
- Comments close: 2026-11-03
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-12

## In one line

FDA Wants Ideas for Sci-Fi Drug Network Revolutionizing Medicine

## Summary

The Center for Drug Evaluation and Research (CDER) within the Food and Drug Administration (FDA or Agency), through its Quantitative Medicine Center of Excellence (QM CoE), is announcing a request for information to inform the development of a Quantitative Medicine Innovation Network (QMIN). The vision for the QMIN is to create a cross-sector collaborative platform that accelerates the translation of quantitative medicine approaches to transform drug development, regulatory science, and clinical decision-making for patient benefit. The purpose of this request is to obtain feedback from industry, academia, healthcare providers, patient groups, and other interested parties on identifying critical community needs and establishing mechanisms for continuous engagement, supporting collaborative demonstration projects or research on innovative approaches aimed at addressing high priority areas through the application of QM approaches, and exploring mechanisms to leverage community expertise and capacity to promote QM innovation and adoption. Information submitted in response to this request will be considered in shaping the structure, priorities, and activities of the QMIN.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-15887 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/05/2026-15887/establishment-of-a-quantitative-medicine-innovation-network-scope-feasibility-and-opportunities)
- [2026-15887 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-05/pdf/2026-15887.pdf)

## Related
- [Previous: 2026-15885, Combined Notice of Filings #1](https://policyrisk.com/federal-register/2026-15885)
- [Next: 2026-15888, Combined Notice of Filings #2](https://policyrisk.com/federal-register/2026-15888)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-15887 (as of 2026-08-12).